{"transactions":[{"id":3180,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T21:30:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7657,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As contemplated by the Merger Agreement, the reported options were vested as of the date of the merger of Andor Merger Co. with and into the Issuer, with the Issuer surviving as an indirectly wholly owned subsidiary of AbbVie Inc. (the \"Merger\"), or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak held the options reported herein for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Kiselak was obligated to turn over to Fairmount any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaimed beneficial ownership of the option and underlying common stock."}],"balance_after":0,"derivative":{"exercise_price":85,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001104659-26-105119","document":"tm2624730-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926105119/tm2624730-1_4seq1.xml","form_type":"4"}},{"id":3179,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T21:30:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14461,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As contemplated by the Merger Agreement, the reported options were vested as of the date of the merger of Andor Merger Co. with and into the Issuer, with the Issuer surviving as an indirectly wholly owned subsidiary of AbbVie Inc. (the \"Merger\"), or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak held the options reported herein for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Kiselak was obligated to turn over to Fairmount any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaimed beneficial ownership of the option and underlying common stock."}],"balance_after":0,"derivative":{"exercise_price":41.66,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14461},"source":{"system":"sec-edgar","filing":"0001104659-26-105119","document":"tm2624730-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926105119/tm2624730-1_4seq1.xml","form_type":"4"}},{"id":3178,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T21:30:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10370,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As contemplated by the Merger Agreement, the reported options were vested as of the date of the merger of Andor Merger Co. with and into the Issuer, with the Issuer surviving as an indirectly wholly owned subsidiary of AbbVie Inc. (the \"Merger\"), or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak held the options reported herein for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Kiselak was obligated to turn over to Fairmount any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaimed beneficial ownership of the option and underlying common stock."}],"balance_after":0,"derivative":{"exercise_price":43.85,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":10370},"source":{"system":"sec-edgar","filing":"0001104659-26-105119","document":"tm2624730-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926105119/tm2624730-1_4seq1.xml","form_type":"4"}},{"id":3177,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T21:30:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":47758,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"As contemplated by the Merger Agreement, the reported options were vested as of the date of the merger of Andor Merger Co. with and into the Issuer, with the Issuer surviving as an indirectly wholly owned subsidiary of AbbVie Inc. (the \"Merger\"), or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the Merger Consideration of $135.11 over the exercise price of such option."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak held the options reported herein for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Kiselak was obligated to turn over to Fairmount any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaimed beneficial ownership of the option and underlying common stock."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2033-07-13","underlying":"Common Stock","underlying_shares":47758},"source":{"system":"sec-edgar","filing":"0001104659-26-105119","document":"tm2624730-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926105119/tm2624730-1_4seq1.xml","form_type":"4"}},{"id":3176,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Voting Common Stock","published_at":"2026-09-03T21:30:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6743321,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The shares of non-voting common stock had no expiration date and were convertible in accordance with the terms of the Issuer's Amended and Restated Certificate of Incorporation at any time at the option of the holder into shares of common stock of the Issuer on a 1-for-1 basis without consideration to the extent that after giving effect to such conversion the holders thereof, together with their affiliates and any members of a Section 13(d) group with such holders, would beneficially own, for purposes of Rule 13d-3 under the Securities Act of 1934, as amended, no more than 9.99% of the outstanding shares of common stock immediately prior to and following such conversion, which percentage may have been changed at a holder's election upon 61 days' notice to the Issuer, provided that the percentage may not have exceeded 19.99%."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the \"Merger Agreement\"), in exchange for a cash payment equal to $135.11 per Share without interest (the \"Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the \"Merger Agreement\"), in exchange for a cash payment equal to $135.11 per Share without interest (the \"Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the \"Merger Agreement\"), in exchange for a cash payment equal to $135.11 per Share without interest (the \"Merger Consideration\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6743321},"source":{"system":"sec-edgar","filing":"0001104659-26-105119","document":"tm2624730-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926105119/tm2624730-1_4seq1.xml","form_type":"4"}},{"id":3175,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-03T21:30:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":51166,"ownership":{"direct":false,"nature":"By Peter Harwin"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the \"Merger Agreement\"), in exchange for a cash payment equal to $135.11 per Share without interest (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-105119","document":"tm2624730-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926105119/tm2624730-1_4seq1.xml","form_type":"4"}},{"id":3174,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-03T21:30:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":51166,"ownership":{"direct":false,"nature":"By Tomas Kiselak"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the \"Merger Agreement\"), in exchange for a cash payment equal to $135.11 per Share without interest (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-105119","document":"tm2624730-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926105119/tm2624730-1_4seq1.xml","form_type":"4"}},{"id":3173,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-03T21:30:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":340855,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each reported security was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc. (the \"Merger Agreement\"), in exchange for a cash payment equal to $135.11 per Share without interest (the \"Merger Consideration\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-105119","document":"tm2624730-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926105119/tm2624730-1_4seq1.xml","form_type":"4"}},{"id":2651,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:17.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7657,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":85,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001140361-26-035615","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035615/form4.xml","form_type":"4"}},{"id":2650,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:17.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14461,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":41.66,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14461},"source":{"system":"sec-edgar","filing":"0001140361-26-035615","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035615/form4.xml","form_type":"4"}},{"id":2649,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:17.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10370,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":43.85,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":10370},"source":{"system":"sec-edgar","filing":"0001140361-26-035615","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035615/form4.xml","form_type":"4"}},{"id":2648,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:17.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":23.6,"expiration_date":"2033-08-17","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001140361-26-035615","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035615/form4.xml","form_type":"4"}},{"id":2647,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-09-03T20:39:17.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-26-035615","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035615/form4.xml","form_type":"4"}},{"id":2655,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:16.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7657,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":85,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001140361-26-035614","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035614/form4.xml","form_type":"4"}},{"id":2654,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:16.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14461,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":41.66,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14461},"source":{"system":"sec-edgar","filing":"0001140361-26-035614","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035614/form4.xml","form_type":"4"}},{"id":2653,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:16.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10370,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":43.85,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":10370},"source":{"system":"sec-edgar","filing":"0001140361-26-035614","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035614/form4.xml","form_type":"4"}},{"id":2652,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-09-03T20:39:16.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34824,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-26-035614","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035614/form4.xml","form_type":"4"}},{"id":2660,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":83690,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":75.78,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":83690},"source":{"system":"sec-edgar","filing":"0001140361-26-035613","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1983476/000114036126035613/form4.xml","form_type":"4"}},{"id":2659,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":124962,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":49.07,"expiration_date":"2034-12-09","underlying":"Common Stock","underlying_shares":124962},"source":{"system":"sec-edgar","filing":"0001140361-26-035613","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1983476/000114036126035613/form4.xml","form_type":"4"}},{"id":2658,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":110665,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":110665},"source":{"system":"sec-edgar","filing":"0001140361-26-035613","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1983476/000114036126035613/form4.xml","form_type":"4"}},{"id":2657,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-03T20:39:14.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":167123,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-26-035613","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1983476/000114036126035613/form4.xml","form_type":"4"}},{"id":2656,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-03T20:39:14.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1375,"price":135.06,"value":185707.5,"ownership":{"direct":true},"balance_after":167123,"source":{"system":"sec-edgar","filing":"0001140361-26-035613","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1983476/000114036126035613/form4.xml","form_type":"4"}},{"id":2665,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:12.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7657,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":85,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001140361-26-035612","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035612/form4.xml","form_type":"4"}},{"id":2664,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:12.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14461,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":41.66,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14461},"source":{"system":"sec-edgar","filing":"0001140361-26-035612","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035612/form4.xml","form_type":"4"}},{"id":2663,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:12.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10370,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":43.85,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":10370},"source":{"system":"sec-edgar","filing":"0001140361-26-035612","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035612/form4.xml","form_type":"4"}},{"id":2662,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-09-03T20:39:12.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34824,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-26-035612","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035612/form4.xml","form_type":"4"}},{"id":2672,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:11.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":83690,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":75.78,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":83690},"source":{"system":"sec-edgar","filing":"0001140361-26-035611","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035611/form4.xml","form_type":"4"}},{"id":2671,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:11.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":124962,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":49.07,"expiration_date":"2034-12-09","underlying":"Common Stock","underlying_shares":124962},"source":{"system":"sec-edgar","filing":"0001140361-26-035611","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035611/form4.xml","form_type":"4"}},{"id":2670,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:11.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":175345,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":175345},"source":{"system":"sec-edgar","filing":"0001140361-26-035611","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035611/form4.xml","form_type":"4"}},{"id":2669,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-03T20:39:11.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":158371,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-26-035611","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035611/form4.xml","form_type":"4"}},{"id":2685,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1950,"kind":"person","name":"Bollinger Lisa","position":1,"cik":"0002024557","reported_name":"Bollinger Lisa","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:09.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7657,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":85,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001140361-26-035610","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2024557/000114036126035610/form4.xml","form_type":"4"}},{"id":2684,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1950,"kind":"person","name":"Bollinger Lisa","position":1,"cik":"0002024557","reported_name":"Bollinger Lisa","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:09.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14461,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":41.66,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14461},"source":{"system":"sec-edgar","filing":"0001140361-26-035610","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2024557/000114036126035610/form4.xml","form_type":"4"}},{"id":2683,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1950,"kind":"person","name":"Bollinger Lisa","position":1,"cik":"0002024557","reported_name":"Bollinger Lisa","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:09.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8112,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":43.85,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":8112},"source":{"system":"sec-edgar","filing":"0001140361-26-035610","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2024557/000114036126035610/form4.xml","form_type":"4"}},{"id":2682,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1950,"kind":"person","name":"Bollinger Lisa","position":1,"cik":"0002024557","reported_name":"Bollinger Lisa","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:09.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18550,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each reported option was disposed of, pursuant to the Agreement and Plan of Merger, dated as of June 18, 2026, among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc., in exchange for a cash payment equal to the excess of the merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":47.86,"expiration_date":"2034-05-28","underlying":"Common Stock","underlying_shares":18550},"source":{"system":"sec-edgar","filing":"0001140361-26-035610","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2024557/000114036126035610/form4.xml","form_type":"4"}},{"id":2689,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:07.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":253016,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":75.78,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":253016},"source":{"system":"sec-edgar","filing":"0001140361-26-035609","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035609/form4.xml","form_type":"4"}},{"id":2688,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:07.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":357036,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":49.07,"expiration_date":"2034-12-09","underlying":"Common Stock","underlying_shares":357036},"source":{"system":"sec-edgar","filing":"0001140361-26-035609","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035609/form4.xml","form_type":"4"}},{"id":2687,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:07.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":387012,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each reported option was disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the per share merger consideration of $135.11 over the exercise price of such option."}],"balance_after":0,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":387012},"source":{"system":"sec-edgar","filing":"0001140361-26-035609","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035609/form4.xml","form_type":"4"}},{"id":2686,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-03T20:39:07.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":920941,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities represent shares of the Issuer's common stock disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of June 18, 2026 (the \"Merger Agreement\"), among Andor LLC, Andor Merger Co., the Issuer and AbbVie Inc."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-26-035609","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035609/form4.xml","form_type":"4"}},{"id":2679,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1948,"kind":"person","name":"Shah Nimish P","position":1,"cik":"0001698082","reported_name":"Shah Nimish P","relationship":{"director":true}}],"security":"Pre-Funded Warrants (Right to Buy)","published_at":"2026-09-03T20:39:06.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":365853,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The exercise price of each reported warrant is $0.00001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each reported option and warrant was disposed of in connection with the Merger in exchange for a cash payment equal to the excess of $135.11 (the per share merger consideration) over the exercise price of such option or warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The reported warrants had no expiration date and were exercisable immediately upon grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The reported warrants had no expiration date and were exercisable immediately upon grant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The reported warrants are held directly by Venrock Opportunities Fund, L.P. (\"VOF\"). Venrock Opportunities Management, LLC (\"VO Management\") is the general partner of VOF. The Reporting Person is a voting member of VO Management and expressly disclaims beneficial ownership over all shares held by VOF except to the extent of his indirect pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":365853},"source":{"system":"sec-edgar","filing":"0001140361-26-035608","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035608/form4.xml","form_type":"4"}},{"id":2678,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1948,"kind":"person","name":"Shah Nimish P","position":1,"cik":"0001698082","reported_name":"Shah Nimish P","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:06.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7657,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each reported option and warrant was disposed of in connection with the Merger in exchange for a cash payment equal to the excess of $135.11 (the per share merger consideration) over the exercise price of such option or warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"Under an agreement between the Reporting Person and Venrock Management, LLC (the \"Management Company\"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":85,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001140361-26-035608","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035608/form4.xml","form_type":"4"}},{"id":2677,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1948,"kind":"person","name":"Shah Nimish P","position":1,"cik":"0001698082","reported_name":"Shah Nimish P","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:06.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14461,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each reported option and warrant was disposed of in connection with the Merger in exchange for a cash payment equal to the excess of $135.11 (the per share merger consideration) over the exercise price of such option or warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"Under an agreement between the Reporting Person and Venrock Management, LLC (the \"Management Company\"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":41.66,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":14461},"source":{"system":"sec-edgar","filing":"0001140361-26-035608","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035608/form4.xml","form_type":"4"}},{"id":2676,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1948,"kind":"person","name":"Shah Nimish P","position":1,"cik":"0001698082","reported_name":"Shah Nimish P","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:06.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10370,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each reported option and warrant was disposed of in connection with the Merger in exchange for a cash payment equal to the excess of $135.11 (the per share merger consideration) over the exercise price of such option or warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"Under an agreement between the Reporting Person and Venrock Management, LLC (the \"Management Company\"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":43.85,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":10370},"source":{"system":"sec-edgar","filing":"0001140361-26-035608","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035608/form4.xml","form_type":"4"}},{"id":2675,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1948,"kind":"person","name":"Shah Nimish P","position":1,"cik":"0001698082","reported_name":"Shah Nimish P","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T20:39:06.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":47758,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each reported option and warrant was disposed of in connection with the Merger in exchange for a cash payment equal to the excess of $135.11 (the per share merger consideration) over the exercise price of such option or warrant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The reported options were vested as of the date of the Merger or became fully vested in connection with the Merger."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F7","text":"Under an agreement between the Reporting Person and Venrock Management, LLC (the \"Management Company\"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2033-07-13","underlying":"Common Stock","underlying_shares":47758},"source":{"system":"sec-edgar","filing":"0001140361-26-035608","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035608/form4.xml","form_type":"4"}},{"id":2674,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1948,"kind":"person","name":"Shah Nimish P","position":1,"cik":"0001698082","reported_name":"Shah Nimish P","relationship":{"director":true}}],"security":"Non-Voting Common Stock","published_at":"2026-09-03T20:39:06.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6743321,"price":135.11,"value":911090100.31,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Non-Voting Common Stock was convertible at any time and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Non-Voting Common Stock was convertible at any time and had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"The reported securities, which were disposed of in connection with the Merger, represent (i) 2,495,319 shares of Non-Voting Common Stock held directly by VHCP III, (ii) 249,522 shares of Non-Voting Common Stock held directly by VHCP Co-III and (iii) 3,998,480 shares of Non-Voting Common Stock held directly by VHCP EG."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"VHCP Management III, LLC (\"VHCPM III\") is the sole general partner of VHCP III and the sole manager of VHCP Co-III. VHCP Management EG, LLC (\"VHCPM EG\") is the sole general partner of VHCP EG. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM III and VHCPM EG. Dr. Koh, Mr. Shah, VHCPM III and VHCPM EG disclaim beneficial ownership over all shares held by VHCP III, VHCP Co-III, and VHCP EG, except to the extent of their respective indirect pecuniary interests therein."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":6743321},"source":{"system":"sec-edgar","filing":"0001140361-26-035608","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035608/form4.xml","form_type":"4"}},{"id":2673,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1948,"kind":"person","name":"Shah Nimish P","position":1,"cik":"0001698082","reported_name":"Shah Nimish P","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-09-03T20:39:06.000Z","date":"2026-09-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1750000,"price":135.11,"value":236442500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities, which were disposed of in connection with the acquisition of the Issuer by AbbVie Inc. (the \"Merger\"), represent (i) 460,075 shares of the Issuer's common stock (\"Common Stock\") held by Venrock Healthcare Capital Partners III, L.P. (\"VHCP III\"), (ii) 46,025 shares held by VHCP Co-Investment Holdings III, LLC (\"VHCP Co-III\") and (iii) 1,243,900 shares held by Venrock Healthcare Capital Partners EG, L.P. (\"VHCP EG\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"VHCP Management III, LLC (\"VHCPM III\") is the sole general partner of VHCP III and the sole manager of VHCP Co-III. VHCP Management EG, LLC (\"VHCPM EG\") is the sole general partner of VHCP EG. Dr. Bong Koh and Nimish Shah are the voting members of VHCPM III and VHCPM EG. Dr. Koh, Mr. Shah, VHCPM III and VHCPM EG disclaim beneficial ownership over all shares held by VHCP III, VHCP Co-III, and VHCP EG, except to the extent of their respective indirect pecuniary interests therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-26-035608","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000114036126035608/form4.xml","form_type":"4"}},{"id":690295,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-11T20:30:25.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":false,"shares":10370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option represented the right to purchase 10,370 shares of the Issuer's common stock, which vested on the one-year anniversary of the 6/5/2024 grant date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (the \"Adviser\"), Mr. Harwin held the options reported herein for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). Mr. Harwin was obligated to turn over to the Adviser any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaimed beneficial ownership of the option and underlying common stock."}],"balance_after":0,"derivative":{"exercise_price":43.85,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":10370},"source":{"system":"sec-edgar","filing":"0001104659-26-094087","document":"tm2622705-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465926094087/tm2622705-1_4seq1.xml","form_type":"4"}},{"id":690294,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-11T20:30:25.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":false,"shares":31838,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represented the vested portion of the total right to purchase 47,758 shares of the Issuer's common stock, which vested in three approximately equal annual installments beginning on the first anniversary of the 7/13/2023 grant date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (the \"Adviser\"), Mr. Harwin held the options reported herein for one or more investment vehicles managed by the Adviser (each, a \"Fairmount Fund\"). Mr. Harwin was obligated to turn over to the Adviser any net cash or stock received from the options for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaimed beneficial ownership of the option and underlying common stock."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2033-07-13","underlying":"Common Stock","underlying_shares":31838},"source":{"system":"sec-edgar","filing":"0001104659-26-094087","document":"tm2622705-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465926094087/tm2622705-1_4seq1.xml","form_type":"4"}},{"id":690293,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T20:30:25.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":true,"shares":10370,"price":43.85,"value":454724.5,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":340855,"source":{"system":"sec-edgar","filing":"0001104659-26-094087","document":"tm2622705-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465926094087/tm2622705-1_4seq1.xml","form_type":"4"}},{"id":690292,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2223,"kind":"person","name":"Fairmount Healthcare Fund II L.P.","position":2,"cik":"0001769651","reported_name":"Fairmount Healthcare Fund II L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":3,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2225,"kind":"person","name":"Harwin Peter Evan","position":4,"cik":"0001663607","reported_name":"Harwin Peter Evan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-11T20:30:25.000Z","date":"2026-08-07","kind":"exercise","planned":false,"acquired":true,"shares":31838,"price":17,"value":541246.0,"ownership":{"direct":false,"nature":"By Fairmount Healthcare Fund II LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Fairmount Funds Management LLC (\"Fairmount\") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein."}],"balance_after":330485,"source":{"system":"sec-edgar","filing":"0001104659-26-094087","document":"tm2622705-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1663607/000110465926094087/tm2622705-1_4seq1.xml","form_type":"4"}},{"id":692680,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-08T00:00:09.000Z","date":"2026-08-05","kind":"exercise","planned":true,"acquired":false,"shares":4125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":110665,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":4125},"source":{"system":"sec-edgar","filing":"0001104659-26-092838","document":"tm2622546-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926092838/tm2622546-1_4seq1.xml","form_type":"4"}},{"id":692679,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-08T00:00:09.000Z","date":"2026-08-05","kind":"sale","planned":true,"acquired":false,"shares":5500,"price":134.17,"value":737935.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."}],"balance_after":168498,"source":{"system":"sec-edgar","filing":"0001104659-26-092838","document":"tm2622546-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926092838/tm2622546-1_4seq1.xml","form_type":"4"}},{"id":692678,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-08T00:00:09.000Z","date":"2026-08-05","kind":"exercise","planned":true,"acquired":true,"shares":4125,"price":22.86,"value":94297.5,"ownership":{"direct":true},"balance_after":173998,"source":{"system":"sec-edgar","filing":"0001104659-26-092838","document":"tm2622546-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926092838/tm2622546-1_4seq1.xml","form_type":"4"}},{"id":703469,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-25T00:00:20.000Z","date":"2026-07-24","kind":"gift","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund."}],"balance_after":158371,"source":{"system":"sec-edgar","filing":"0001104659-26-086729","document":"tm2621304-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926086729/tm2621304-1_4seq1.xml","form_type":"4"}},{"id":707774,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-17T00:00:13.000Z","date":"2026-07-14","kind":"gift","planned":false,"acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund."}],"balance_after":169873,"source":{"system":"sec-edgar","filing":"0001104659-26-084344","document":"tm2620587-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926084344/tm2620587-1_4seq1.xml","form_type":"4"}},{"id":710992,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-10T20:00:17.000Z","date":"2026-07-10","kind":"gift","planned":true,"acquired":false,"shares":75046,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction involves a bona fide gift of securities from the reporting person to a donor advised fund."}],"balance_after":920941,"source":{"system":"sec-edgar","filing":"0001104659-26-082758","document":"tm2620107-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926082758/tm2620107-1_4seq1.xml","form_type":"4"}},{"id":710991,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-10T20:00:17.000Z","date":"2026-07-08","kind":"sale","planned":true,"acquired":false,"shares":20000,"price":133.63,"value":2672600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $133.52 to $133.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":995987,"source":{"system":"sec-edgar","filing":"0001104659-26-082758","document":"tm2620107-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926082758/tm2620107-1_4seq1.xml","form_type":"4"}},{"id":716926,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-03T00:13:06.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":4125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":114790,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":4125},"source":{"system":"sec-edgar","filing":"0001104659-26-080477","document":"tm2619720-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926080477/tm2619720-1_4seq1.xml","form_type":"4"}},{"id":716925,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-03T00:13:06.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":5500,"price":132.74,"value":730070.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."}],"balance_after":177873,"source":{"system":"sec-edgar","filing":"0001104659-26-080477","document":"tm2619720-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926080477/tm2619720-1_4seq1.xml","form_type":"4"}},{"id":716924,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-03T00:13:06.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":4125,"price":22.86,"value":94297.5,"ownership":{"direct":true},"balance_after":183373,"source":{"system":"sec-edgar","filing":"0001104659-26-080477","document":"tm2619720-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926080477/tm2619720-1_4seq1.xml","form_type":"4"}},{"id":727216,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-25T00:01:46.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":26400,"price":132.6,"value":3500640.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.550 to $132.645, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":179248,"source":{"system":"sec-edgar","filing":"0001104659-26-077427","document":"tm2618514-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926077427/tm2618514-1_4seq1.xml","form_type":"4"}},{"id":727251,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-25T00:00:37.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":80000,"price":132.54,"value":10603200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.50 to $132.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1015987,"source":{"system":"sec-edgar","filing":"0001104659-26-077426","document":"tm2618514-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926077426/tm2618514-2_4seq1.xml","form_type":"4"}},{"id":739075,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-12T21:05:08.000Z","date":"2026-06-10","kind":"sale","planned":true,"acquired":false,"shares":614,"price":86.89,"value":53350.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.835 to $87.165, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1095987,"source":{"system":"sec-edgar","filing":"0001104659-26-073567","document":"tm2617750-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926073567/tm2617750-1_4seq1.xml","form_type":"4"}},{"id":739074,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-12T21:05:08.000Z","date":"2026-06-10","kind":"sale","planned":true,"acquired":false,"shares":2305,"price":86.27,"value":198852.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.74 to $86.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1096601,"source":{"system":"sec-edgar","filing":"0001104659-26-073567","document":"tm2617750-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926073567/tm2617750-1_4seq1.xml","form_type":"4"}},{"id":739073,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-12T21:05:08.000Z","date":"2026-06-10","kind":"sale","planned":true,"acquired":false,"shares":1577,"price":85.19,"value":134344.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.71 to $85.665, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1098906,"source":{"system":"sec-edgar","filing":"0001104659-26-073567","document":"tm2617750-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926073567/tm2617750-1_4seq1.xml","form_type":"4"}},{"id":739072,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-12T21:05:08.000Z","date":"2026-06-10","kind":"sale","planned":true,"acquired":false,"shares":1080,"price":84.18,"value":90914.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.595 to $84.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1100483,"source":{"system":"sec-edgar","filing":"0001104659-26-073567","document":"tm2617750-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926073567/tm2617750-1_4seq1.xml","form_type":"4"}},{"id":739071,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-12T21:05:08.000Z","date":"2026-06-10","kind":"sale","planned":true,"acquired":false,"shares":7654,"price":82.78,"value":633598.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.57 to $83.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1101563,"source":{"system":"sec-edgar","filing":"0001104659-26-073567","document":"tm2617750-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926073567/tm2617750-1_4seq1.xml","form_type":"4"}},{"id":739070,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-12T21:05:08.000Z","date":"2026-06-10","kind":"sale","planned":true,"acquired":false,"shares":6770,"price":82.21,"value":556561.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.57 to $82.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1109217,"source":{"system":"sec-edgar","filing":"0001104659-26-073567","document":"tm2617750-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926073567/tm2617750-1_4seq1.xml","form_type":"4"}},{"id":741115,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":2222,"kind":"person","name":"Fairmount Funds Management LLC","position":1,"cik":"0001802528","reported_name":"Fairmount Funds Management LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":2224,"kind":"person","name":"Kiselak Tomas","position":2,"cik":"0001830177","reported_name":"Kiselak Tomas","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T00:04:19.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":7657,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By: Tomas Kiselak"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC ('Fairmount'), Mr. Kiselak holds the option for one or more investment vehicles managed by Fairmount (each, a \"Fairmount Fund\"). Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein."}],"balance_after":7657,"derivative":{"exercise_price":85,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001104659-26-073062","document":"tm2617578-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802528/000110465926073062/tm2617578-2_4seq1.xml","form_type":"4"}},{"id":741726,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1948,"kind":"person","name":"Shah Nimish P","position":1,"cik":"0001698082","reported_name":"Shah Nimish P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T00:03:40.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":7657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under an agreement between the Reporting Person and Venrock Management, LLC (the \"Management Company\"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company and must exercise the reported option solely upon the direction of the Management Company, which is entitled to the shares underlying the option. The Management Company may be deemed the indirect beneficial owner of the shares underlying the option, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares underlying the option through his interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein."}],"balance_after":7657,"derivative":{"exercise_price":85,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001104659-26-073061","document":"tm2617578-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1698082/000110465926073061/tm2617578-6_4seq1.xml","form_type":"4"}},{"id":741149,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1940,"kind":"person","name":"McKenna Mark C.","position":1,"cik":"0001749623","reported_name":"McKenna Mark C.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T00:03:09.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":7657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date."}],"balance_after":7657,"derivative":{"exercise_price":85,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001104659-26-073060","document":"tm2617578-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1749623/000110465926073060/tm2617578-5_4seq1.xml","form_type":"4"}},{"id":741280,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1941,"kind":"person","name":"JONES WILLIAM A JR","position":1,"cik":"0001373097","reported_name":"JONES WILLIAM A JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T00:02:30.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":7657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date."}],"balance_after":7657,"derivative":{"exercise_price":85,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001104659-26-073059","document":"tm2617578-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1373097/000110465926073059/tm2617578-1_4seq1.xml","form_type":"4"}},{"id":741086,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1945,"kind":"person","name":"Fox Jennifer A.","position":1,"cik":"0001841557","reported_name":"Fox Jennifer A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T00:01:53.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":7657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date."}],"balance_after":7657,"derivative":{"exercise_price":85,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001104659-26-073058","document":"tm2617578-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1841557/000110465926073058/tm2617578-3_4seq1.xml","form_type":"4"}},{"id":741076,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1950,"kind":"person","name":"Bollinger Lisa","position":1,"cik":"0002024557","reported_name":"Bollinger Lisa","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T00:00:07.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":7657,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date."}],"balance_after":7657,"derivative":{"exercise_price":85,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001104659-26-073056","document":"tm2617578-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926073056/tm2617578-4_4seq1.xml","form_type":"4"}},{"id":747334,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-06T00:00:14.000Z","date":"2026-06-03","kind":"exercise","planned":true,"acquired":false,"shares":4125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":118915,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":4125},"source":{"system":"sec-edgar","filing":"0001104659-26-071076","document":"tm2616980-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926071076/tm2616980-1_4seq1.xml","form_type":"4"}},{"id":747333,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-06T00:00:14.000Z","date":"2026-06-03","kind":"sale","planned":true,"acquired":false,"shares":5500,"price":78.71,"value":432905.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."}],"balance_after":205648,"source":{"system":"sec-edgar","filing":"0001104659-26-071076","document":"tm2616980-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926071076/tm2616980-1_4seq1.xml","form_type":"4"}},{"id":747332,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-06T00:00:14.000Z","date":"2026-06-03","kind":"exercise","planned":true,"acquired":true,"shares":4125,"price":22.86,"value":94297.5,"ownership":{"direct":true},"balance_after":211148,"source":{"system":"sec-edgar","filing":"0001104659-26-071076","document":"tm2616980-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926071076/tm2616980-1_4seq1.xml","form_type":"4"}},{"id":776500,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-16T00:00:12.000Z","date":"2026-05-13","kind":"sale","planned":true,"acquired":false,"shares":1341,"price":82.58,"value":110739.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.470 to $83.265, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1115987,"source":{"system":"sec-edgar","filing":"0001104659-26-062867","document":"tm2614621-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926062867/tm2614621-1_4seq1.xml","form_type":"4"}},{"id":776499,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-16T00:00:12.000Z","date":"2026-05-13","kind":"sale","planned":true,"acquired":false,"shares":18659,"price":82.05,"value":1530970.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.455 to $82.440, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1117328,"source":{"system":"sec-edgar","filing":"0001104659-26-062867","document":"tm2614621-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926062867/tm2614621-1_4seq1.xml","form_type":"4"}},{"id":786150,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-09T00:00:09.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":false,"shares":4125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":123040,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":4125},"source":{"system":"sec-edgar","filing":"0001104659-26-058129","document":"tm2613976-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926058129/tm2613976-1_4seq1.xml","form_type":"4"}},{"id":786149,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-09T00:00:09.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":1800,"price":84.6,"value":152280.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.44 to $84.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":207023,"source":{"system":"sec-edgar","filing":"0001104659-26-058129","document":"tm2613976-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926058129/tm2613976-1_4seq1.xml","form_type":"4"}},{"id":786148,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-09T00:00:09.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":3700,"price":83.92,"value":310504.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.35 to $84.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (\"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":208823,"source":{"system":"sec-edgar","filing":"0001104659-26-058129","document":"tm2613976-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926058129/tm2613976-1_4seq1.xml","form_type":"4"}},{"id":786147,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-09T00:00:09.000Z","date":"2026-05-06","kind":"exercise","planned":true,"acquired":true,"shares":4125,"price":22.86,"value":94297.5,"ownership":{"direct":true},"balance_after":212523,"source":{"system":"sec-edgar","filing":"0001104659-26-058129","document":"tm2613976-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926058129/tm2613976-1_4seq1.xml","form_type":"4"}},{"id":793702,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-05T00:00:16.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":289,"price":83.16,"value":24033.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.090 to $83.190, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":173371,"source":{"system":"sec-edgar","filing":"0001104659-26-055091","document":"tm2613425-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926055091/tm2613425-1_4seq1.xml","form_type":"4"}},{"id":793701,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-05T00:00:16.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":900,"price":82.6,"value":74340.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.040 to $82.995, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":173660,"source":{"system":"sec-edgar","filing":"0001104659-26-055091","document":"tm2613425-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926055091/tm2613425-1_4seq1.xml","form_type":"4"}},{"id":793700,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-05T00:00:16.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":811,"price":81.02,"value":65707.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.640 to $81.260, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":174560,"source":{"system":"sec-edgar","filing":"0001104659-26-055091","document":"tm2613425-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926055091/tm2613425-1_4seq1.xml","form_type":"4"}},{"id":804257,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-20T20:05:28.000Z","date":"2026-04-16","kind":"exercise","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase 398,512 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments over a four-year period from the date of grant, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":387012,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001104659-26-045482","document":"tm2612090-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926045482/tm2612090-2_4seq1.xml","form_type":"4"}},{"id":804256,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-20T20:05:28.000Z","date":"2026-04-16","kind":"exercise","planned":false,"acquired":true,"shares":3000,"price":22.86,"value":68580.0,"ownership":{"direct":true},"balance_after":1135987,"source":{"system":"sec-edgar","filing":"0001104659-26-045482","document":"tm2612090-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926045482/tm2612090-2_4seq1.xml","form_type":"4"}},{"id":805516,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-18T00:00:15.000Z","date":"2026-04-16","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":90,"value":180000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."}],"balance_after":175371,"source":{"system":"sec-edgar","filing":"0001104659-26-045062","document":"tm2612090-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926045062/tm2612090-1_4seq1.xml","form_type":"4"}},{"id":810111,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-11T00:00:11.000Z","date":"2026-04-08","kind":"sale","planned":true,"acquired":false,"shares":200,"price":85,"value":17000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."}],"balance_after":1132987,"source":{"system":"sec-edgar","filing":"0001104659-26-042155","document":"tm2611503-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926042155/tm2611503-1_4seq1.xml","form_type":"4"}},{"id":810110,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-11T00:00:11.000Z","date":"2026-04-08","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":83.26,"value":166520.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.00 to $83.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1133187,"source":{"system":"sec-edgar","filing":"0001104659-26-042155","document":"tm2611503-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926042155/tm2611503-1_4seq1.xml","form_type":"4"}},{"id":810109,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-04-11T00:00:11.000Z","date":"2026-04-08","kind":"sale","planned":true,"acquired":false,"shares":17800,"price":82.48,"value":1468144.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.00 to $82.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1135187,"source":{"system":"sec-edgar","filing":"0001104659-26-042155","document":"tm2611503-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926042155/tm2611503-1_4seq1.xml","form_type":"4"}},{"id":815181,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-04T00:00:49.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":false,"shares":4125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":127165,"derivative":{"exercise_price":22.86,"expiration_date":"2033-12-18","underlying":"Common Stock","underlying_shares":4125},"source":{"system":"sec-edgar","filing":"0001104659-26-039709","document":"tm2611042-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926039709/tm2611042-1_4seq1.xml","form_type":"4"}},{"id":815180,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-04T00:00:49.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":100,"price":85.89,"value":8589.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."}],"balance_after":208398,"source":{"system":"sec-edgar","filing":"0001104659-26-039709","document":"tm2611042-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926039709/tm2611042-1_4seq1.xml","form_type":"4"}},{"id":815179,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-04T00:00:49.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":2702,"price":85.33,"value":230561.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.87 to $85.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon\nrequest, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":208498,"source":{"system":"sec-edgar","filing":"0001104659-26-039709","document":"tm2611042-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926039709/tm2611042-1_4seq1.xml","form_type":"4"}},{"id":815178,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-04T00:00:49.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":2698,"price":84.31,"value":227468.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.87 to $84.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and\nExchange Commission (\"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":211200,"source":{"system":"sec-edgar","filing":"0001104659-26-039709","document":"tm2611042-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926039709/tm2611042-1_4seq1.xml","form_type":"4"}},{"id":815177,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1942,"kind":"person","name":"Dambkowski Carl","position":1,"cik":"0001983476","reported_name":"Dambkowski Carl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-04-04T00:00:49.000Z","date":"2026-04-01","kind":"exercise","planned":true,"acquired":true,"shares":4125,"price":22.86,"value":94297.5,"ownership":{"direct":true},"balance_after":213898,"source":{"system":"sec-edgar","filing":"0001104659-26-039709","document":"tm2611042-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926039709/tm2611042-1_4seq1.xml","form_type":"4"}},{"id":816117,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-04T00:00:08.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":1100,"price":85.46,"value":94006.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.17 to $85.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":177371,"source":{"system":"sec-edgar","filing":"0001104659-26-039708","document":"tm2611042-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926039708/tm2611042-2_4seq1.xml","form_type":"4"}},{"id":816116,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-04T00:00:08.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":900,"price":84.46,"value":76014.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $84.15 to $85.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (\"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":178471,"source":{"system":"sec-edgar","filing":"0001104659-26-039708","document":"tm2611042-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926039708/tm2611042-2_4seq1.xml","form_type":"4"}},{"id":826289,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1947,"kind":"person","name":"Henderson Jane","position":1,"cik":"0001422304","reported_name":"Henderson Jane","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-28T00:00:19.000Z","date":"2026-03-25","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":85,"value":170000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 2, 2025."}],"balance_after":179371,"source":{"system":"sec-edgar","filing":"0001104659-26-036332","document":"tm269945-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1422304/000110465926036332/tm269945-1_4seq1.xml","form_type":"4"}},{"id":843429,"issuer":{"id":1939,"kind":"organization","name":"Apogee Therapeutics, Inc.","symbol":"APGE"},"owners":[{"id":1951,"kind":"person","name":"HENDERSON MICHAEL THOMAS","position":1,"cik":"0001779990","reported_name":"HENDERSON MICHAEL THOMAS","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-03-14T00:00:08.000Z","date":"2026-03-11","kind":"sale","planned":true,"acquired":false,"shares":3418,"price":75.86,"value":259289.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.585 to $76.480, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1152987,"source":{"system":"sec-edgar","filing":"0001104659-26-027802","document":"tm268769-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1779990/000110465926027802/tm268769-1_4seq1.xml","form_type":"4"}}],"next_cursor":"2026-03-14T00:00:08.000000Z,843429"}